We defined the prevalence and impact on survival of clinical bedside variables in 385 patients with symptomatic congestive heart failure (CHF), of whom there were 176 with and 209 without diabetes mellitus. Patients were consecutively hospitalized and admitted for various acute conditions. Following discharge all-cause mortality was recorded. Prevalence and association of various variables with mortality were statistically analyzed. Prevailing in the diabetics versus nondiabetics were younger age (p < 0.05), pulmonary edema on admission (p = 0.002), using furosemide >80 mg/day (p < 0.01) for >1 year (p < 0.01) and hyponatremia (p = 0.01). Less prevalent were chronic lung disease (p < 0.01) and cardiac arrhythmias (p = 0.001). On follow-up extending up to 60 months, diabetic patients, especially those with fasting blood glucose levels on admission ≧180 mg/dl, survived for a shorter period of time than nondiabetics (p = 0.02). Associated with increased mortality in the diabetic group were female gender (p = 0.04), furosemide ≧80 mg/day (p < 0.001) and renal dysfunction (RD; p = 0.04). The respective variables in the nondiabetics were advanced age (p < 0.001) and RD (p = 0.002). Although they were younger, diabetic patients presented more severe CHF. It is recommended that special attention should be given to diabetic females, those using higher furosemide dosages and those suffering from RD.

Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979;241:2035–2038.
Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC: Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017–1020.
Soläng L, Malmberg K, Ryden L: Diabetes mellitus and congestive heart failure. Eur Heart J 1999;20:789–795.
Ryden L, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Packer M, Poole-Wilson PA: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000;21:1967–1978.
He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161:996–1002.
Nichols GA, Hillier TA, Erbey JR, Brown JB: Congestive heart failure in type 2 diabetes: Prevalence, incidence and risk factors. Diabetes Care 2001;24:1614–1619.
Melchior T, Rask-Madsen C, Torp-Pedersen C, Hildebrandt P, Kober L, Jensen G: The impact of heart failure on prognosis of diabetic and non-diabetic patients with myocardial infarction: A 15-year follow-up study. Eur J Heart Fail 2001;3:83–90.
Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, Grobbee DE: The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 2001;22:1318–1327.
Bell DS: Heart failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26:2433–2441.
Bauters C, Lamblin N, Mc Fadden EP, Van Belle E, Millaire A, De Groote P: Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2003;2:1.
Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR; BEST Investigators: The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003;42:914–922.
Opasich C, Cafiero M, Scherillo M, De Feo S, Caputo F, Gonzini L, Lavecchia R, Loru F, Maggioni AP; TEMISTOCLE Investigators: Impact of diabetes on the current in-hospital management of heart failure. From the TEMISTOCLE study. Ital Heart J 2003;4:685–694.
Aronson D, Burger AJ: Diabetes and the occurrence of ventricular arrhythmic events in patients with severe ventricular dysfunction. Diabetologia 2002;45:1440–1445.
Taegtmeyer H, McNulty P, Young ME: Adaptation and maladaptation of the heart in diabetes. I. General concepts. Circulation 2002;105:1727–1733.
Balkau B, Pyörälä M, Shipley M, Forhan A, Jarrett J, Eschwëge E, Pyörälä K: Non-cardiovascular disease mortality and diabetes mellitus. Lancet 1997;350:1680.
Koskinen SV, Reunanen AR, Martelin TP, Valkonen T: Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. Am J Public Health 1998;88:765–770.
Savage MP, Krolewski AS, Kenien GG, Lebeis MP, Christlieb AR, Lewis SM: Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 1988;62:665–669.
Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ: Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001;38:421–428.
Leier CV, Dei Cas L, Metra M: Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994;128:564–574.
Melchior T, Gadsboll N, Hildebrandt P, Kober L, Torp-Pedersen C: Clinical characteristics, left and right ventricular ejection fraction, and long-term prognosis in patients with non-insulin-dependent diabetes surviving an acute myocardial infarction. Diabet Med 1996;13:450–456.
Senni M, Redfield MM: Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 2001;38:1277–1282.
Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA: Outcome of congestive heart failure in elderly persons: Influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002;137:631–639.
Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681–689.
Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D: Survival after onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107–115.
Adams KF Jr, Sueta CA, Gheorghiade M, O’Connor CM, Schwartz TA, Koch GG, Uretsky B, Swedberg K, McKenna W, Soler-Soler J, Califf RM: Gender differences in survival in advanced heart failure. Insights from the FIRST study. Circulation 1999;99:1816–1821.
Kimmelstiel CD, Konstam MA: Heart failure in women. Cardiology 1995;86:304–309.
Ofili EO, Mayberry R, Alema-Mensah E, Saleem S, Hamirani K, Jones C, Salih S, Lankford B, Oduwole A, Igho-Pemu P: Gender differences and practice implications of risk factors for frequent hospitalization for heart failure in an urban center serving predominantly African-American patients. Am J Cardiol 1999;83:1350–1355.
Harjai KJ, Dinshaw HK, Nunez E, Shah M, Thompson H, Turgut T, Ventura HO: The prognostic implications of outpatient diuretic dose in heart failure. Int J Cardiol 1999;71:219–225.
Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K: Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 1995;91:2591–2595.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.